Atossa Therapeutics announced its support of the U.S. Food and Drug Administration, FDA, for issuing a final rule to update the mammography regulations issued under the Mammography Quality Standards Act of 1992, MQSA, which becomes effective today. Among the updates, the final rule requires mammography facilities to provide patients with an assessment of breast density in patient friendly terms. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Atos Shares Drop on Reduced Financial Targets
- Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
- Atossa Therapeutics granted U.S. patent for endoxifen
- Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Questions or Comments about the article? Write to editor@tipranks.com